How AI Will Accelerate Breakthroughs in Biotechnology with Benchling CEO Sajith Wickramasekara - No Priors: Artificial Intelligence | Technology | Startups Recap
Podcast: No Priors: Artificial Intelligence | Technology | Startups
Published: 2025-11-13
Duration: 48 min
Guests: Sajith Wickramasekara
Summary
Sajith Wickramasekara, CEO of Benchling, discusses the transformative role of AI in biotechnology, focusing on how it can streamline drug discovery and development, making processes faster, cheaper, and more effective.
What Happened
Sajith Wickramasekara, CEO of Benchling, delves into how AI is revolutionizing biotechnology by optimizing drug discovery processes. He outlines the current landscape where making a drug involves a complex, multi-step process that can take up to 10 years and cost over $2 billion. Wickramasekara explains that AI can help shorten this cycle by making research and development more efficient, thus reducing failures in late stages of drug development.
The episode highlights how Benchling's AI initiatives are aimed at providing scientists with better tools for simulation and experiment recommendation. Wickramasekara notes that Benchling AI assists in automating mundane tasks, allowing scientists to focus on more complex problems and make quicker decisions based on comprehensive data.
Wickramasekara also discusses how the biotech industry has been affected by a macroeconomic downturn similar to the dot-com bust, but he remains optimistic about AI's potential to drive the next wave of innovation. He believes that the industry's future will focus on speed and cost-efficiency, with AI playing a pivotal role in achieving these goals.
The conversation shifts to the global landscape, noting China's growing influence in biotech due to its ability to rapidly and cost-effectively develop new drugs. This has led to a shift in where large pharma companies source new molecules, increasingly turning to Chinese biotech firms.
Wickramasekara emphasizes the importance of structured data and the role of platforms like Benchling in making this data accessible and actionable for scientists. He explains that while large pharma companies are not yet fully transformed by AI, they are investing in data generation capabilities that could lead to unique predictive models.
The episode concludes with insights into company culture and building interdisciplinary teams, which Benchling has done by integrating software and scientific expertise. Wickramasekara shares his belief that more transparency and storytelling in biotech could help change public perception and encourage further innovation.
Key Insights
- AI can reduce the drug development cycle, which traditionally takes up to 10 years and costs over $2 billion, by optimizing research and development processes and minimizing late-stage failures.
- Benchling's AI initiatives automate routine tasks and enhance experiment recommendations, allowing scientists to focus on complex problems and make faster, data-driven decisions.
- China's biotech industry is gaining prominence due to its ability to develop new drugs rapidly and cost-effectively, influencing large pharmaceutical companies to source new molecules from Chinese firms.
- Large pharmaceutical companies are investing in data generation capabilities to create unique predictive models, although they have not yet fully integrated AI into their operations.